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ABSTRACT 
Branchio-oto-renal (BOR) syndrome is an autosomal dominant disorder characterized by 
branchial, ear and renal anomalies. Over 80 mutations in EYA1 have been reported in BOR. 
Mutations in SIX1, a DNA binding protein that associates with EYA1, have been reported less 
frequently. One group has recently described 4 missense mutations in SIX5 in 5 unrelated 
patients with BOR.  
Here, we report a screening of these three genes in a cohort of 140 patients from 124 families 
with BOR. We identified 36 EYA1 mutations in 42 unrelated patients, 2 mutations and one 
change of unknown significance in SIX1 in 3 unrelated patients, but no mutation in SIX5. We 
did not find correlation between genotype and phenotype, and observed a high phenotypic 
variability between and within BOR families. We show the difficulty in establishing a 
molecular diagnosis strategy in BOR syndrome: the screening focusing on patients with 
typical BOR would detect a mutation rate of 76%, but would also miss mutations in 9% of 
patients with atypical BOR. We detected a deletion removing three EYA1 exons in a patient 
who was previously reported to carry the SIX5 Thr552Met mutation. This led us to reconsider 
the role of SIX5 in the development of BOR. 
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INTRODUCTION 
Branchio-oto-renal (BOR) syndrome is an autosomal-dominant developmental disorder which 
is characterized by hearing loss, branchial arch defects and various renal anomalies. The 
prevalence of BOR syndrome is estimated to be 1 case per 40 000 (Chen et al., 1995; Fraser et 
al., 1978; Fraser et al., 1980, Melnick et al., 1975, Melnick et al., 1978). The syndrome is 
clinically heterogeneous and has a high penetrance with variable expressivity (Fraser et al., 
1978, Fraser et al., 1980, Chen et al., 2004). BOR syndrome is also genetically heterogeneous. 
Over 80 mutations in EYA1 (MIM ID 601653), the human homolog of the Drosophila eyes 
absent gene, encoding a transcriptional regulator, have been identified. These include large 
and small heterozygous deletions, frameshift, stop, splice-site and missense heterozygous 
mutations (Abdelhak et al., 1997b, Ni et al., 1994, Vincent et al., 1997). The rate of detection 
of EYA1 mutations varies from 7% to 40% of patients tested according to the clinical criteria 
required for molecular testing (Abdelhak et al., 1997a, Abdelhak et al., 1997b, Chang et al., 
2004, Orten et al., 2008). Mutations in SIX1 (MIM ID 601205) (mainly missense mutations 
and small deletions), the human homolog of sine oculis encoding a DNA binding protein that 
associates with EYA1, have also been associated with BOR syndrome (Kochhar et al., 2008, 
Ruf et al., 2003, Ruf et al., 2004, Sanggaard et al., 2007), though much less frequently than 
EYA1 mutations. More recently, missense mutations in another SIX family member, SIX5 
(MIM ID 600963), have been reported by one group in patients with BOR syndrome (Hoskins 
et al., 2007). SIX5 homologous is known to interact with eya-1 in C. elegans. In vitro 
functional analyses of the BOR-associated SIX5 variants showed that some of these variants 
modified EYA1-SIX5 binding and the ability of the EYA1-SIX5 complex to transactivate a 
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reporter gene (Hoskins et al., 2007).  However, the association of SIX5 mutations with BOR 
syndrome has not been confirmed by other groups.  
In the present study, we screen for EYA1, SIX1 and SIX5 mutations a large cohort of patients 
with BOR syndrome. We describe the clinical features associated with the mutations and the 
rate of mutations identified, according to the clinical phenotypes. We also show that one 
family previously reported as carrying a SIX5 missense mutation harbors a heterozygous 
deletion of three EYA1 exons, which therefore questions the role of the reported SIX5 change. 
 
PATIENTS AND METHODS 
Patients 
A total of 140 patients from 124 families with a diagnosis of BOR syndrome were included in 
the study. Subjects were classified according to the criteria defined by Chang (Chang et al., 
2004) on the basis of clinical history, audiometry and renal ultrasonography. Patients were 
considered as typical BOR when they had at least three major criteria (branchial anomalies, 
deafness, preauricular pits or renal anomalies), or two major and two minor criteria (internal, 
middle and/or external ear anomalies, preauricular tags, facial asymmetry or palatine 
anomalies) or one major criterion and an affected first-degree relative meeting the above 
criteria for typical BOR. Other were considered as atypical BOR and were tested only when 
they demonstrated at least two features of the syndrome.  
Patient 1062 was previously reported as carrying a heterozygous SIX5 c.1655C>T 
(p.Thr552Met) mutation (patient A500 in Hoskins et al.). His DNA had been tested for EYA1 
mutations by direct sequencing, but not for abnormal copy number (Hoskins et al., 2007). 
This patient was having assisted reproduction, and thus was making inquiries regarding the 
possibility of preimplantation genetic testing. 
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Patients’ samples, medical records, genealogy and written informed consent from patient 
and/or parents were sent from Paediatric, Paediatric Nephrology, Nephrology, or Genetics 
departments between August 2004 and December 2009.  
 
Mutation analysis 
Genomic DNA was isolated from peripheral blood using standard methods. The 16 exons of 
EYA1 were screened for mutations by direct sequencing. When no mutation was found, 
quantitative multiplex PCR amplification of short fluorescence fragments (Charbonnier et al., 
2000) was performed for EYA1 exons 1, 5, 10, 15 and 16. When a deletion was found to 
remove some but not all of the exons tested, the DNA sample was analysed by multiplex 
ligation dependent probes amplification (Salsa MLPA kit P153 EYA1, MRC-Holland, 
Amsterdam, Netherlands). When neither mutation nor deletion was found in EYA1, the 2 
exons of SIX1 and the 3 exons of SIX5 were screened by direct sequencing. For previously 
unreported missense mutations, 92 control individuals were tested by direct sequencing. The 
cDNAs NM_172060.2 for EYA1, NM_005982.3 for SIX1 and NM_175875.4 for SIX5 were 
used for numbering, with nt +1 corresponding to the A of the ATG translation initiation 
codon. One DNA sample (patient 608), was shown to have large 8q13.3 deletion by FISH 
analysis and was used as a positive control for deletion screening. Missense mutations were 
evaluated using the softwares PolyPhen (http://genetics.bwh.harvard.edu/pph/) and ConSurf 
(http://consurftest.tau.ac.il/).   
 
Statistical tests 
Testing for difference in proportions was performed using either the X2 or Fisher’s exact test. 
All tests were two sided. P-values <0.05 were considered significant. 
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RESULTS 
Mutations  
The mutations identified and the associated phenotypes are shown in table 1. In the entire 
cohort (140 patients from 124 families) we identified 36 EYA1 mutations in 42 families (55 
patients), two SIX1 mutations and one SIX1 variant of unknown significance in 3 families (4 
patients), but no SIX5 mutation. We identified two SIX5 variants which were not considered 
to be responsible for the phenotype: one was found in controls, and the other, previously 
reported as a disease causing mutation in two families (Hoskins et al., 2007), was associated 
with a partial EYA1 deletion in one of these two families included in our cohort. Therefore, 
mutations were identified in 36% (45/124) of the tested families. 
EYA1 gene analysis 
Thirty-six EYA1 heterozygous mutations, spread over the entire length of the gene (figure 1), 
were identified in 42 probands (table 1). Thirty-three were small mutations (8 missense 
including a mutation of the stop codon, 14 frameshift, 6 stop, and 5 splice-site mutations), and 
24 of these were novel. All missense mutations but one [c.319G>A (p.Gly107Ser)] were 
considered as possibly or probably damaging by the PolyPhen software 
(http://genetics.bwh.harvard.edu/pph/). That mutation c.319G>A, which appeared de novo in 
the patient, was scored as benign by Polyphen but was in the last base of exon 4 and thus was 
expected to modify the splicing of intron 4 (GeneSplicer score changes from 6.97 to 2.49) . 
Amino acid conservation scores according to ConSurf (varying from 1 to 9) for previously 
unpublished missense mutations are shown in table 1.Two previously reported mutations, 
c.982C>T and c.1220G>A, were respectively found in three and two unrelated patients. Three 
different deletions were identified in 5 unrelated patients by quantitative multiplex PCR 
amplification of short fluorescence fragments. In 3 of these probands (patients 608, 821, 991) 
all tested exons were missing and the deletion was considered to remove the entire gene. In 
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the other two cases, the deletion was partial and its precise extent was determined by MLPA 
analysis: one removed exons 8 to 16 (patient 1216) and one removed exons 3, 4 and 5 
(patients 1062, 1063 and 1064). Patient 1062 was one of the 2 probands previously reported to 
carry the SIX5 p.Thr552Met mutation (patient A500 in Hoskins, et al., 2007). Parent status 
was tested for 26 probands with an identified EYA1 mutation : 8 mutations out of 26 were de 
novo and 18 were inherited. 
 
SIX1 gene analysis 
Three different, potentially pathogenic variations in SIX1 were identified in 3 families (table 
1). The SIX1 mutation (p.Tyr129Cys) has already been described (Ruf et al., 2004), and 
affects a conserved tyrosine in the homeodomain. It is predicted to be probably damaging by 
Polyphen (score 2.945), and inhibits the transcription activation in vitro (Patrick et al., 2009). 
This mutation was also present in the affected father of the proband. The mutation 
c.560+3A>T, probably leading to aberrant splicing (GeneSplicer score changes from 9.74 to 
2.89), has never been previously described. Finally, the c.746C>T change in exon 2 affects a 
strongly conserved amino acid (p.Pro249Leu) and was considered as possibly damaging by 
PolyPhen (score 1.806). Although this change was not present in 92 healthy control 
chromosomes it is located in a region of unknown function and replaces a non polar side 
chain amino acid with another amino acid of the same family. The segregation of these two 
last changes could not be tested because DNA samples from family members were not 
available.  
 
SIX5 gene analysis 
We did not identify any novel SIX5 mutations in our entire cohort. We confirmed the finding 
of the SIX5 p.Thr552Met heterozygous variant in patient 1062, and also found the same SIX5 
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variant in his twin brother (patient 1063) and in his father (patient 1064), who were both 
affected. This variant was predicted as possibly damaging by the Polyphen program (score 
1.711). However, we identified an EYA1 partial deletion in the three affected members of this 
family (see above). We found another SIX5 variant, c.156_161dup (p.Gly55Ala56dup), in a 
patient from Guadeloupe. That variant, which introduces two amino acids in the N-terminus 
of the protein, was also found in 3/86 controls from the West Indies and thus was considered 
as non pathogenic.  
 
Phenotypes (tables 1 and 2) 
According to previously described criteria (Chang et al., 2004), our population included 67 
patients with typical BOR and 55 patients with atypical BOR. In 18 cases the information we 
had was insufficient to classify patients as typical or atypical. Sixty eight probands had a 
family history of BOR (38 typical cases of BOR and 30 cases of renal anomaly, branchial 
arches defects and/or deafness, which did not fulfill the typical BOR diagnosis criteria). The 
phenotypic features of patients with an identified mutation are detailed in table 1. 
The frequency of each symptom in our entire population as well as in patients with mutation 
and in patients without mutation is summarized in table 2. The various renal phenotypes 
observed in patients with an identified mutation are described figure 2. The renal function of 
these patients varied greatly, from a normal glomerular filtration rate to end-stage renal 
failure. In four cases prenatal renal failure diagnosed by oligoamnios during the second 
trimester of pregnancy was observed in fetuses displaying kidney hypoplasia (patients 175, 
700, 991 and 1126), and this led to termination of pregnancy in three of these cases. Five 
patients received a renal transplant: two reached end stage renal failure during childhood (at 
14 and 16 years), one at 26 years, and two others at unknown age (but one received a 
transplant at 22). In some families (see cases 700 and 1126 as examples), although a fetus or a 
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child had severe renal disease, the affected parent had normal renal function and normal 
kidneys on ultrasound examination. After renal disease, the most frequent symptom was 
deafness (conductive and/or sensorineural), followed by pits, branchial defect and then by ear 
tags.  
Some patients presented with rare phenotypic features. In patients with an identified mutation, 
two (patients 311 and 1291) presented with cataract (unilateral in one case and bilateral in the 
other). Five patients had facial nerve impairment: unilateral facial paralysis, crocodile tears 
syndrome and facial asymmetry. Palate anomalies were observed in 5 patients: short palate 
responsible for hypernasal speech, arched palate, palatine cleft, bifid uvula and posterior 
agenesia of uvula. We observe two heart defects: a persistent ductus arteriosus in patient 708 
and a conotroncal cardiopathy (pulmonary atresia with interventricular communication) in 
patient 700. Finally, patient 229 suffered from hypothyroidism of unknown etiology. 
In patients without any identified mutation, rare clinical features were also observed : palate 
or laryngeal anomalies (n=4), facial asymmetry (n=2), bifid uterus (n=2), interventricular 
communication (n=2), clinodactyly (n=1), aortic arch hypoplasia (n=1), cutaneous 
pigmentation anomalies (n=2), Malherbe’s calcifying epithelioma  (n=1), dorsal medullar 
atrophia responsible for pyramidal syndrome (n=1), pulmonary hypertension of unknown 
etiology (n=1), cerebral ventricular dilation (n=1), thyroglossal duct cyst (n=1), jejuno-ileal 
atresia (n=1), and bone anomalies (radial aplasia, mandibular hypoplasia, dental agenesis, 
postaxial polydactyly) in four patients. 
Genotype-phenotype correlation 
Because the type and severity of the symptoms were very variable, we searched whether there 
was a correlation between the phenotype and either the mutated gene (EYA1 or SIX1) or  the 
type of mutation (missense mutation, truncating mutation because of stop, frameshift, or 
splice-site mutation), or deletion. Of the 67 patients with typical BOR syndrome, 50 (75%),  
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had a mutation in EYA1, and one had a change in SIX1 of unknown significance. Of the 55 
patients with atypical BOR syndrome, 5 (9%) had a mutation (in EYA1 in 4 cases and in SIX1 
in 1 case). The proportion of patients affected with typical or atypical BOR syndrome was not 
significantly different (p=0.38) between patients carrying a missense mutation (9/11 typical), 
a truncating mutation (34/37 typical) or a deletion (8/8 typical). The same mutation 
(p.Arg328X) was identified in a patient with atypical BOR and in 2 patients with typical 
BOR. We did not observed any particular phenotypic features associated with SIX1 mutations. 
Rare features were observed both in patients carrying EYA1 or SIX1 mutations (assuming that 
the SIX1 p.Pro249Leu is responsible for the phenotype). Among the 55 patients with EYA1 
mutations, the proportion of deletion (n=9), missense (n=10), and truncating (n=36) mutations 
was not significantly different between patients with (n=40) or without (n=15) deafness 
(p=0,46), with (n=30) or without (n=25) kidney involvement (p=0.35), with (n=32) or without 
(n=23) pits (p=1), or with (n=34) or without (n=11) branchial defect (p=0.66) (Table 3). 
Regarding the renal disease, cases with prenatal renal failure associated with oligoamnios 
(n=4) or with severe renal failure leading to renal transplant (n=5) were associated with SIX1 
mutations in one case, and with EYA1 mutations in 7 cases. These proportions were not 
significantly different from that observed in all patients. However, in the 7 cases with EYA1 
mutations, none of these mutations were a missense mutations (3 were frameshift, 1 splice-
site, 1 stop and 2 were entire gene deletions).  
 
DISCUSSION  
To our knowledge, this study is the first one to analyze all of the genes currently known to be 
implicated in BOR syndrome in a large cohort of patients. Overall, we detected a mutation in 
45/124 (36%) probands. Forty two probands were carrying an EYA1 mutation thought to be 
pathogenic. However, the impact of the c.867+5G>A change on mRNA splicing has not yet 
Deleted: nonsense 
Page 10 of 29
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 11 
been demonstrated. Three probands were carrying mutations in SIX1. Of these, one (patient 
714) was carrying the c.806C>T, p.Pro249Leu change, which has never been described 
before, and is predicted to be possibly damaging by Polyphen. This mutation was not found in 
92 control chromosomes, but does not affect a protein domain with a known function. All 
other SIX1 mutations reported so far affect either the SIX or the homeodomain encoding 
nucleotides  (Kochhar et al., 2008, Ruf et al., 2004). We were unable to test other family 
members of patients 714 and 715, so it is difficult to conclude whether this change is or not a 
disease-causing mutation. 
In our entire cohort, we did not identify any pathogenic mutation in the SIX5 gene. In one 
patient previously reported to carry a SIX5 missense variant (case 1062), we found a partial 
(exons 3-5) EYA1 deletion. The three affected patients in this family were carrying both the 
EYA1 deletion and the SIX5 variant. We believe that the EYA1 deletion is responsible for the 
phenotype in this family, though we cannot rule out the hypothesis that the SIX5 variant may 
modify the EYA1-associated phenotype. However, whereas the three patients had deafness, 
the renal disease was more severe in the two siblings (undergoing renal transplantation at 22 
and 23 years of age) than in their father (who had not reached end-stage renal failure at 58 
years). This was despite the fact that all three carried the SIX5 variant. The finding of an EYA1 
mutation in that family made us reconsider the role of SIX5 in the development of BOR 
syndrome. Among the 5 index cases reported by Hoskins et al. as carrying a SIX5 mutation 
(Hoskins et al., 2007), all carried a missense variant, including two cases with the c.1655C>T 
p.Thr552Met variant (patient 1062 and another patient). The segregation of the variants with 
the phenotype had not been studied. These variants modestly (20 to 48%) although 
significantly decreased the ability of SIX5/EYA1 to activate gene transcription in vitro 
(Hoskins et al., 2007). No other SIX5 mutation (whether missense or other type of 
mutation/rearrangment) has been reported since this initial report. In addition, whereas mice 
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with Six1 or Eya1 gene inactivation develop ear and kidney abnormalities, the phenotype in 
Six5-/- mice is limited to abnormalities in the eye (cataract), and does not affect the ear or the 
kidney. Taken together, these findings strongly suggest that SIX5 mutations are not directly 
responsible for BOR syndrome. 
Among the patients that were classified with either typical or atypical BOR (122 patients), we 
identified a mutation in 75% of cases with typical BOR syndrome and in 9% of cases with 
atypical BOR syndrome. These results are different from those reported recently in a smaller 
cohort in which no mutations were detected in any subject with atypical BOR (Rickard et al., 
2008). This highlights the difficulty in reconciling the need for performing molecular testing 
in a consequential and cost effective manner, and the fact that a screening limited to typical 
BOR syndrome will miss few mutations and prevent accurate genetic counselling in these few 
families. The rate of mutation that we report here is not different from that recently reported 
in another large cohort (Orten et al., 2008). However, the rate of EYA1 deletion in the present 
study is lower than that (18%) reported by Chang et al. (Chang et al., 2004). Although we 
used the same semiquantitative fluorescence multiplex PCR approach for tracking EYA1 
deletions,  we only tested exons 1, 5, 10, 15, and 16 in a first attempt. We may have thus 
missed small or complex deletions involving other exons.  
In our series as in others (Chang et al., 2004, Ruf et al., 2004, Saanggard et al., 2007, Okada 
et al., Orten et al., 2008), the type and severity of the phenotype does not seem to correlate 
with the type of mutation and is very variable, even within a given family. Only the severity 
of renal failure may correlate to some extent with the type of EYA1 mutation, as none of the 7 
patients with the most severe renal insufficiency were carrying a missense mutation. However 
the small number of patients does not allow any conclusion to be made, and it would be 
interesting to analyze the severity of the renal failure in a larger number of cases carrying an 
EYA1 mutation. The high frequency of renal anomalies in our series may be due to the fact 
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that our laboratory is focused on renal diseases. The important phenotypic variability 
observed in our cohort as in others may be due to genetic and/or environmental factors (in 
particular maternal factors during embryonic and fetal development) that modify the 
phenotype. This makes genetic counselling particularly difficult for these families.  
We report some interesting clinical features associated with EYA1 mutations. Although 
already reported by others (Chen et al., 1995, Shimasaki et al., 2004) the association with 
hypothyroidism or with persistent ductus arteriosus may be fortuitous, as may be the 
association with a conotruncal cardiopathy. Two patients suffered from cataract, which could 
be associated with a defect of early expression of EYA1 in the anterior ocular segment, and 
has already been described (Azuma et al., 2000). A facial nerve impairment was present in six 
patients, which may be explained by anomalies of inner ear, affecting the nerve trajectory.  
In conclusion, our results confirm that EYA1 is by far the most frequently mutated gene in 
BOR syndrome today and seriously question the role of SIX5 variants in the pathophysiology 
of BOR syndrome. They confirm the lack of genotype-phenotype correlation and illustrate the 
difficulty in establishing an algorithm for molecular diagnosis in BOR syndrome. The 
screening of patients with typical BOR only would greatly increase the rate of identified 
mutations but would also lead to missed mutations in a few families. Our data suggest that 
testing patients with atypical BOR still results in the identification of a few mutations, but 
screening of the SIX5 gene can be given up. 
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Figure legend 
Figure 1 : Schematic representation of  EYA1 gene. Boxes represent EYA1 exons. Mutations: 
frameshift , nonsense , missense  , splice site , deletion                
EyaHR: eyes absent homologous region. 
 
Figure 2: Renal phenotypes in patients with an identified mutation. 
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Patient Family history Phenotype Rare features Gene Exon or IVS Nucleotide change 
Protein change 
(conservation 
score**) 
Polyphen Mutation inheritance  Reference 
Possibly 
damaging 346   T b, f   EYA1 4 c.184C>T p.Pro62Ser* (5) 
Score 1,851 
I 
  
this study 
673   U b, d (r : U)   EYA1 4 c.303C>A p.Tyr101X - N BTNRH, unpublished 
Benign 
383   T b, p, r Language delay EYA1 4 c.319G>A p.Gly107Ser* (7) 
Score 0,456 
N 
  
this study 
656   T d, p, r, f   EYA1 5 c.430C>T p.Gln144X - U this study 
1126 T r, f, TOP Potter's sequence I 
1318 
 
1126 patient's 
father T b, d, f   
EYA1 7 c.586_596Dup (+)636_644delInsTG p.Ser200IlefsX12 -  U this study 
1153   T d, p, r, ie   EYA1 7 c.616dupT p.Tyr206LeufsX50   U this study 
708   T b, p, ee (d : U) 
Lacrymal duct stenosis, 
bifid uvula, persistent 
ductus arteriosus 
EYA1 7 c.670delC p.Gln224SerfsX109 - U this study 
311   T  d, p, ee, t Cataract, facial 
asymmetry EYA1 7 c.722delC p.Thr241LysfsX92 - I this study 
523   T d, p, ee, f (r : U)   U 
1215 BOR in her 
mother T b, r, ee, f   
EYA1 8 c.781C>T p.Arg261X - 
U 
Kumar et al, 1998 
326   T b, p, f (d  and r : U)   I 
327 326 patient's 
mother T b, d, f   
EYA1 8 c.783delA p.Leu262CysfsX71 - 
U 
this study 
1291   A b, p Bilateral cataract EYA1 IVS8 c.867+5G>A -  -  U this study 
1311   T b, d, p, ee Facial paresia EYA1 8 c.867_867+14del p.Arg290GlufsX43  - U this study 
314   T b, d, p, ie, f Epicanthus, hypernasal 
speech EYA1 IVS9 c.952-2A>G - - I Okada et al, 2006 
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117   T b, d, r   U 
332   A r, ee (d : U) 
Dysmorphic features, 
arched palate, unilateral 
ovarian agenesia 
U 
347   T b, p, r, ee   
EYA1 10 c.982C>T p.Arg328X - 
N 
BTNRH, unpublished 
512   T b, d, p, r, ee, ie, f 
Motor delay, cleft 
palate, lacrymal duct 
agenesis 
Probably 
damaging I 
417 512 patient’s 
mother T b, d, r, ee, ie, f   
EYA1 10 c.989A>T p.Glu330Val* (9) 
Score 2,568 U 
this study 
1056   T b, p, ee, ie, t, f   - I 
1057 1056 patient's father T d, p, ee, f Facial asymetria 
EYA1 10 c.1039G>T p.Glu374X 
- U 
this study 
1282   T b, d, p, r   EYA1 IVS 10 c.1042-1G>A - - U MORL 
1288   T b, d, p, r   EYA1 IVS 11 c.1100+1G>C - - U  this study 
693   T b, d, r, ee, ie   EYA1 12 c.1216_1219dup p.Arg407GlnfsX13 - U this study 
1194   T b, p, r, ee, t Crocodile tears 
syndrome 
Possibly 
damaging  U 
1202 BOR in his father T b, d, f   
EYA1 12 c.1220G>A p.Arg407Gln (5) 
Score 1.766 U 
Kumar et al, 1997 
1321   T b, d, r, ee   EYA1 12 c.1231_1232dupAT p.Tyr412SerfsX24 - U this study 
780   T b, p, f   I 
781   T b, d, p, ee, f   I 
782 780 and 781 patients' mother T b, d, p   I 
783 782 patient's grand-mother T d, f   
EYA1 12 c.1251delinsCC p.Asn418GlnfsX10 - 
U 
Abdelhak et al, 1997 
285   T b, d, p, r, ee, ie, f   N 
286 285 patient's 
mother T b, d, p, r, f   
EYA1 13 c.1372_1375dupTCCC p.Arg459LeufsX41 - 
U 
this study 
175   T  r, ee, f, (d : U), TOP Fetal hypotrophia EYA1 IVS13 c.1377-2A>G - - I BTNRH, unpublished 
548 900 and 700 patients' father T b, d, p, f   U 
900   T d, p, f   I 
700   T r, f, TOP Conotroncal cardiopathy 
EYA1 14 c.1425delA p.Leu476TrpfsX9 - 
I 
this study 
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710   T b, p, r Uvula agenesis EYA1 14 c.1434dup p.Val479SerfsX20 - N this study 
Probably 
damaging 497   A p, d, ee Crocodile tears 
syndrome EYA1 14 c.1442T>C p.Leu481Pro* (8) 
Score 2,517 
N 
  
this study 
Probably 
damaging 229   T p, d, ie, f Hypothyroidism EYA1 14 c.1481A>G p.Tyr494Cys (8) 
Score 3,048 
U 
  
BTNRH, unpublished 
148   T b, d, p, r, ie, t   EYA1 15 c.1542_1546delAAAAG p.Arg514SerfsX83 - U this study 
953   T b, d, r Lacrymal duct stenosis EYA1 15 c.1554T>G p.Tyr518X - U this study 
  
Probably 
damaging 1014   A d, t 
  
EYA1 16 c.1607T>C p.Met536Thr* (9) 
Score 2,723 
U 
  
this study 
483   T  d, p, r, ee, ie   EYA1 16 c.1655dup p.His552GlnfsX47 - I this study 
1265   T d, p, r   EYA1 16 c.1678T>C p.X560Gln*  - U this study 
1062   T b, d, r, t, f   I 
1063 1062 patient's brother T d, r, f   I 
1064 1062 and 1063 patients' father T b, d, t, r, f   
EYA1 3, 4 and 5 c.104- ?_461+?del - - 
U 
this study 
1216   T b, d, p (r : U)   EYA1 8-16 c.727-?_1680+?del - - U this study 
608   T b, d, p, r, ee 
Cutaneous 
mastocytosis, 
hypoplasia of the 
triangular muscle of the 
lip, hypermetropia 
N   
821   T b, d, r, ee, t, f 
Micrognathia, feeding 
troubles, central and 
obstructive apnea 
I   
798 821 patient's 
mother  T b, d, ee, f   U   
991   T b, d, p, r Facial asymmetry 
EYA1 - Entire gene deletion - - 
N   
714   U b (d : U)   Probably damaging I Ruf et al, 2004 
715 714 patient's father U b, ee (d : U)   
SIX1 1 c.386A>G p.Tyr129Cys 
Score 2,945 U   
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1226   A b, p   SIX1 IVS 1 + 3 c.560+3A>T - - U this study 
Possibly 
damaging U this study 162   T r, f Lacrymal duct stenosis SIX1 2 c.746C>T p.Pro249Leu* (7) 
Score 1,806     
 
Table 1 : mutations and phenotypes in patients with BOR syndrome.  : T : typical BOR, A : atypical BOR, b : branchial anomalies, d : deafness, p : pits, t : tags, ie : inner ear, me : middle ear, ee 
: extern ear anomalies, r : renal anomalies, f : familial, U : unknown, TOP : termination of pregnancy, I : inherited, N : de novo. BTNRH and MORL : Boys Town National Research Hospital and 
Molecular Otolaryngology Research Laboratory (UI, USA), see  http://www.healthcare.uiowa.edu/labs/pendredandbor/. * : not found in 92 healthy individuals. ** :according to ConSurf 
(http://consurftest.tau.ac.il/). The reference sequences for numbering are NM_172060.2 for EYA1, NM_005982.3 for SIX1 and NM_175875.4 for SIX5 . 
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 Total With a mutation No mutation 
 n % n % n % 
Renal anomalies 89 65% 31 53% 58 72% 
Deafness 88 64% 40 68% 48 59% 
Pits 56 41% 33 56% 23 28% 
Branchial defects 55 40% 37 63% 18 22% 
Tags 31 23% 8 14% 23 28% 
Table 2 : clinical features of the whole population (n=140). Columns with and without mutation represent the ratio of patients with each symptoms reported on the total number of patients with (n=59) 
or without (n= 81) mutation, respectively 
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  Deafness No deafness Total 
Missense 8 2 10 
Truncating 24 12 36 
Deletion 8 1 9 
  40 15 55 
    
  
Renal 
symptoms 
 No renal 
symptom Total 
Missense 5 5 10 
Truncating 18 18 36 
Deletion 7 2 9 
  30 25 55 
    
  Pits No pit Total 
Missense 6 4 10 
Truncating 22 14 36 
Deletion 4 5 9 
  32 23 55 
    
  
Branchial 
symptoms 
No branchial 
symptom Total 
Missense 6 4 10 
Truncating 22 14 36 
Deletion 6 3 9 
  34 11 55 
 
Table 3: type of EYA1 mutation according to the type of symptom. Deleted: ¶
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Schematic representation of  EYA1 gene. Boxes represent EYA1 exons. Mutations: frameshift , 
nonsense , missense  , splice site , deletion                EyaHR: eyes absent homologous 
region.  
169x94mm (300 x 300 DPI)  
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Renal phenotypes in patients with an identified mutation.  
160x100mm (300 x 300 DPI)  
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